Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROGLYCERIN vs IMDUR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a vasodilator that is converted to nitric oxide (NO) in vascular smooth muscle cells. NO activates guanylyl cyclase, increasing c GMP levels, leading to dephosphorylation of myosin light chains and vasodilation. Predominantly dilates venous capacitance vessels, reducing preload; also dilates coronary arteries at higher doses.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Acute angina pectoris,Prophylaxis of angina pectoris,Acute myocardial infarction (IV formulation),Heart failure associated with acute myocardial infarction (IV),Anal fissure (topical, off-label),Esophageal spasm (off-label)
Prevention of angina pectoris due to coronary artery disease,Off-label: chronic heart failure (as adjunctive therapy), esophageal spasm
Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses for angina; Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours; Intravenous: 5-200 mcg/min continuous infusion for acute coronary syndromes or heart failure; Topical 2% ointment: 15-30 mg (0.5-1 inch) every 6-8 hours.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
Terminal half-life: 1–4 minutes for the parent compound; clinical effects dissipate within the same time frame, correlating with rapid metabolism.
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Metabolized primarily by hepatic glutathione-organic nitrate reductase and cytochrome P450 enzymes (CYP3A4) to inorganic nitrite and denitrated metabolites; also undergoes extrahepatic metabolism in erythrocytes and vascular tissue.
Primarily hepatic metabolism via denitration and glucuronidation; isosorbide mononitrate is the active metabolite of isosorbide dinitrate and does not undergo significant first-pass metabolism.
Metabolized extensively by hepatic glutathione-organic nitrate reductase and other non-specific esterases; renal excretion of metabolites accounts for approximately 50%, with fecal elimination of about 20-30%. Less than 1% of unchanged drug is excreted renally.
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Approximately 60% bound to albumin.
Less than 5%, primarily to albumin. Very low protein binding, which contributes to high free fraction.
Approximately 3.3 L/kg, indicating extensive distribution into tissues.
Volume of distribution is approximately 0.6-0.7 L/kg for isosorbide mononitrate. This moderate Vd indicates distribution into total body water and some tissue binding.
Sublingual: 40–60% due to first-pass metabolism; buccal: 40–60%; transdermal: 10–20% (limited by skin permeability).
Oral bioavailability is nearly 100% for isosorbide mononitrate due to lack of first-pass metabolism (unlike isosorbide dinitrate). For IMDUR extended-release, relative bioavailability is comparable to immediate-release, with controlled release properties.
No dose adjustment required for any degree of renal impairment, including end-stage renal disease.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution; consider starting at 30 mg once daily and titrate slowly.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Consider 25% dose reduction; Child-Pugh Class C: Avoid use or use with extreme caution, consider 50% dose reduction.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%; start at 30 mg once daily. Child-Pugh Class C: Contraindicated or use with extreme caution; start at 30 mg once daily with careful monitoring.
Safety and efficacy not established; limited data: IV infusion 0.25-1 mcg/kg/min titrated to effect; sublingual 5-10 mcg/kg per dose (max 0.6 mg) every 5-10 minutes as needed for angina.
Not approved for pediatric use. Limited data: 0.5-2 mg/kg orally once daily, not to exceed 120 mg once daily.
Start at lowest dose; sublingual 0.3 mg, transdermal 0.2 mg/hour; increased sensitivity to hypotension and syncope; monitor for orthostatic hypotension; may require reduced dosing frequency.
Start at 30 mg once daily; titrate slowly due to increased sensitivity and risk of hypotension.
Do not use nitroglycerin with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) as this can cause severe hypotension. Concomitant use with soluble guanylyl cyclase stimulators (e.g., riociguat) is contraindicated.
Not recommended for use in patients with acute myocardial infarction (MI) or congestive heart failure (CHF) requiring rapid hemodynamic monitoring; use only under close clinical observation.
Hypotension,Tachycardia,Paradoxical bradycardia,Increased intracranial pressure (use with caution in cerebral hemorrhage or head trauma),Hypertrophic cardiomyopathy (may exacerbate outflow obstruction),Tolerance with prolonged use (intermittent dosing with nitrate-free interval recommended),Abrupt withdrawal may precipitate angina
Hypotension: may cause severe hypotension, especially with upright posture,Tolerance: continuous use may lead to tolerance and cross-tolerance to other nitrates; use with a daily nitrate-free interval,Headache: often occurs but may diminish with continued use,Glaucoma: controversial; generally considered safe,Volume depletion: increased risk of hypotension
Hypersensitivity to nitroglycerin or any component,Concomitant use with phosphodiesterase-5 inhibitors (within 24 hours for sildenafil, vardenafil; 48 hours for tadalafil),Concomitant use with soluble guanylyl cyclase stimulators (riociguat),Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Constrictive pericarditis,Pericardial tamponade,Restrictive cardiomyopathy,Acute myocardial infarction with low left ventricular filling pressure,Circulatory failure (shock)
Hypersensitivity to isosorbide mononitrate or other nitrates,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Acute circulatory failure or shock
Avoid alcohol consumption while taking nitroglycerin due to risk of severe hypotension and syncope. No other significant food interactions.
Avoid high-fat meals as they may delay absorption. No specific food interactions; alcohol may increase hypotensive effects.
Insufficient human data; animal studies do not indicate teratogenicity. Avoid in first trimester unless clearly needed. No known increased risk of major malformations. Use caution in third trimester due to potential maternal hypotension reducing uteroplacental perfusion.
FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: No specific malformation pattern identified. Second and third trimesters: Potential risk of fetal hypotension and reduced placental perfusion due to maternal vasodilation.
Excreted into breast milk in very low amounts; M/P ratio not established. Considered compatible with breastfeeding; monitor infant for hypotension.
Unknown if isosorbide mononitrate is excreted in human breast milk. M/P ratio not established. Caution advised; consider discontinuing nursing or drug, balancing importance of drug to mother.
No routine dose adjustment required; however, increased plasma volume may necessitate higher doses for therapeutic effect. Monitor clinical response.
No specific dose adjustments recommended for pregnancy; however, hemodynamic changes (increased plasma volume, cardiac output) may alter pharmacokinetics. Start at lowest effective dose and titrate based on maternal response and tolerability.
Use with caution in patients with hypertrophic obstructive cardiomyopathy due to risk of syncope. Nitroglycerin is contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to severe hypotension. Sublingual tablets should be taken at first sign of angina; if pain persists after 5 minutes, call 911. Tolerance develops with continuous exposure, so use nitrate-free intervals (10-12 hours daily) for transdermal patches. Administer intravenous nitroglycerin with non-PVC tubing to avoid drug absorption. Monitor for hypotension, reflex tachycardia, and headache. Do not use in patients with severe anemia, increased intracranial pressure, or right ventricular infarction.
Imdur (isosorbide mononitrate) is an extended-release nitrate used for angina prophylaxis. Avoid concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Tachyphylaxis can occur with continuous use; maintain a daily nitrate-free interval (typically 10-12 hours) to preserve efficacy. Do not crush or chew extended-release tablets. Monitor blood pressure and heart rate during initiation. Use with caution in patients with hypertrophic obstructive cardiomyopathy, aortic stenosis, or volume depletion.
Take sublingual nitroglycerin at the first sign of chest pain; sit down before taking to prevent dizziness.,Place the tablet under the tongue or in the buccal pouch and allow it to dissolve completely; do not swallow.,If pain is not relieved within 5 minutes, call 911 immediately; you may take a second tablet while waiting.,Do not take this medication if you have taken erectile dysfunction drugs (e.g., sildenafil, tadalafil) within the last 24-48 hours.,Store sublingual tablets in the original glass bottle with the cap tightly closed to protect from light and moisture; do not transfer to another container.,Expect a headache or flushing after taking; these usually diminish with continued use.,If using a transdermal patch, apply to a hairless area of skin and rotate sites daily; remove at bedtime to prevent tolerance.,Avoid alcohol while taking this medication as it can increase the risk of hypotension.,Seek emergency help if you experience severe dizziness, fainting, or difficulty breathing.
Take Imdur exactly as prescribed, usually once daily in the morning to maintain a nitrate-free interval.,Do not crush, chew, or cut the tablet; swallow it whole with a glass of water.,Avoid taking erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on Imdur, as this can cause a dangerous drop in blood pressure.,If you experience headache, it may indicate the drug is working; acetaminophen can help. Inform your doctor if headaches persist.,Store at room temperature, away from moisture and heat.
"Concomitant use of nitroglycerin, a vasodilator that increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, and acebutolol, a cardioselective beta-1 adrenergic blocker, can lead to excessive hypotension and reflex tachycardia. Acebutolol may blunt the compensatory sympathetic response to nitroglycerin-induced vasodilation, while nitroglycerin can counteract the negative chronotropic effects of acebutolol, resulting in unopposed vagal tone and potential bradycardia. This interaction increases the risk of syncope, dizziness, and cardiovascular collapse, particularly in patients with volume depletion or pre-existing heart failure."
"Amobarbital, a barbiturate with hepatic enzyme-inducing properties, may enhance the metabolism of nitroglycerin, potentially reducing its efficacy. However, the primary concern is that amobarbital can cause significant hypotension via central nervous system depression and vasodilation, which, when combined with the vasodilatory effects of nitroglycerin, may lead to additive hypotensive effects, increasing the risk of severe hypotension, syncope, and cardiovascular collapse. This interaction is particularly relevant in patients with coronary artery disease or heart failure, where maintaining adequate blood pressure is critical."
"Concurrent administration of clofarabine, a purine nucleoside antimetabolite, and nitroglycerin, a vasodilator for angina, may lead to additive hypotension. Clofarabine itself can induce hypotension as an adverse effect, and nitroglycerin directly relaxes vascular smooth muscle, resulting in decreased blood pressure. This combination increases the risk of severe hypotension, potentially leading to dizziness, syncope, or falls, especially in patients with pre-existing hypotension or volume depletion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROGLYCERIN vs IMDUR, answered by our medical review team.
NITROGLYCERIN is a Nitrate Vasodilator that works by Nitroglycerin is a vasodilator that is converted to nitric oxide (NO) in vascular smooth muscle cells. NO activates guanylyl cyclase, increasing c GMP levels, leading to dephosphorylation of myosin light chains and vasodilation. Predominantly dilates venous capacitance vessels, reducing preload; also dilates coronary arteries at higher doses.. IMDUR is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROGLYCERIN and IMDUR depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROGLYCERIN is: Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses for angina; Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours; Intravenous: 5-200 mcg/min continuous infusion for acute coronary syndromes or heart failure; Topical 2% ointment: 15-30 mg (0.5-1 inch) every 6-8 hours.. The standard adult dose of IMDUR is: Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROGLYCERIN and IMDUR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROGLYCERIN is classified as Category C. Insufficient human data; animal studies do not indicate teratogenicity. Avoid in first trimester unless clearly needed. No known increased risk of major malformations. Use caution . IMDUR is classified as Category C. FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.